Barclays and Cowen are bookrunning managers; Oppenheimer, Maxim assist
By Devika Patel
Knoxville, Tenn., Sept. 18 – Foamix Pharmaceuticals Ltd. said it priced its $40.2 million initial public offering of stock with a $6.03 million greenshoe. The deal was announced Aug. 13.
The company will sell 6.7 million ordinary shares at $6.00 per share.
Cowen and Co., LLC and BMO Capital Markets Corp. are the joint bookrunning managers.
Settlement is expected Sept. 23.
Proceeds will be used for clinical trials, studies, research and development and other general corporate purposes.
The clinical-stage specialty pharmaceutical company is based in Rehovot, Israel. The company intends to list its common stock on the Nasdaq stock exchange under the symbol “FOMX.”
| Issuer: | Foamix Pharmaceuticals Ltd.
|
| Issue: | Ordinary stock
|
| Amount: | $40.2 million
|
| Greenshoe: | $6.03 million
|
| Shares: | 6.7 million
|
| Price: | $6.00
|
| Warrants: | No
|
| Bookrunners: | Barclays and Cowen and Co., LLC
|
| Co-managers: | Oppenheimer & Co. Inc. and Maxim Group LLC
|
| Announcement date: | Aug. 13
|
| Pricing date: | Sept. 18
|
| Settlement date: | Sept. 23
|
| Stock exchange: | Nasdaq: FOMX
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
